Sara Pusceddu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4835758/publications.pdf

Version: 2024-02-01

74 papers	1,649 citations	331259 21 h-index	315357 38 g-index
75 all docs	75 docs citations	75 times ranked	2681 citing authors

#	Article	IF	Citations
1	The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Neuroendocrinology, 2017, 104, 85-93.	1.2	185
2	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. Oncologist, 2014, 19, 966-974.	1.9	84
3	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. Cancer Treatment Reviews, 2019, 72, 45-55.	3.4	82
4	Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 484.	1.7	79
5	A literature overview of primary cervical malignant melanoma: An exceedingly rare cancer. Critical Reviews in Oncology/Hematology, 2012, 81, 185-195.	2.0	73
6	Everolimus in combination with octreotide longâ€acting repeatable in a firstâ€line setting for patients with neuroendocrine tumors: An ITMO group study. Cancer, 2014, 120, 2457-2463.	2.0	62
7	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Annals of Oncology, 2014, 25, 1597-1603.	0.6	59
8	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine, 2018, 60, 490-498.	1.1	59
9	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology, 2018, 155, 479-489.e7.	0.6	54
10	Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. European Journal of Surgical Oncology, 2017, 43, 380-387.	0.5	51
11	Treatment of lung large cell neuroendocrine carcinoma. Tumor Biology, 2016, 37, 7047-7057.	0.8	46
12	Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis. Radiotherapy and Oncology, 2019, 134, 211-219.	0.3	44
13	Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. Neuroendocrinology, 2020, 110, 616-629.	1.2	43
14	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. Critical Reviews in Oncology/Hematology, 2018, 123, 57-73.	2.0	41
15	Diagnosis and management of typical and atypical lung carcinoids. Critical Reviews in Oncology/Hematology, 2016, 100, 167-176.	2.0	35
16	Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Annals of Oncology, 2007, 18, 1810-1816.	0.6	34
17	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 194-200.	1.8	32
18	Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma. Oncology, 2007, 73, 204-209.	0.9	30

#	Article	IF	Citations
19	Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. Future Oncology, 2016, 12, 1251-1260.	1.1	29
20	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroâ€enteroâ€pancreatic neuroendocrine neoplasms. Journal of Pathology: Clinical Research, 2019, 5, 217-226.	1.3	29
21	Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?. Tumori, 2011, 97, 564-7.	0.6	26
22	Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Therapeutic Advances in Medical Oncology, 2017, 9, 183-188.	1.4	20
23	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). International Journal of Cancer, 2019, 144, 1704-1712.	2.3	20
24	Primary Uterine Cervix Melanoma Resembling Malignant Peripheral Nerve Sheath Tumor: A Case Report. International Journal of Gynecological Pathology, 2008, 27, 596-600.	0.9	19
25	Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis. Neuroendocrinology, 2021, 111, 475-489.	1.2	19
26	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 2018, 18, 198-203.	0.5	18
27	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 607-618.	1.6	18
28	The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. Tumori, 2018, 104, 88-95.	0.6	17
29	Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update. Neuroendocrinology, 2018, 106, 307-311.	1.2	17
30	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. Clinical Lung Cancer, 2021, 22, 161-169.	1.1	17
31	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. Tumor Biology, 2016, 37, 12991-13003.	0.8	16
32	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clinical Colorectal Cancer, 2020, 19, 156-164.	1.0	16
33	Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. Tumori, 2014, 100, e286-9.	0.6	16
34	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. Pancreatology, 2019, 19, 1067-1073.	0.5	15
35	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. Oncotarget, 2016, 7, 44841-44847.	0.8	15
36	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1209-1224.	1.2	14

#	Article	IF	Citations
37	The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. Targeted Oncology, 2018, 13, 333-351.	1.7	14
38	Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups. Cancers, 2020, 12, 2753.	1.7	13
39	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. Targeted Oncology, 2018, 13, 567-582.	1.7	12
40	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. Cancer Medicine, 2017, 6, 1493-1499.	1.3	11
41	Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. Journal of Clinical Medicine, 2020, 9, 2468.	1.0	11
42	Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. Future Oncology, 2015, 11, 1947-1959.	1.1	9
43	Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. Tumori, 2019, 105, 113-120.	0.6	9
44	Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. Cancers, 2022, 14, 69.	1.7	9
45	Safety profile and treatment response of everolimus in different solid tumors: an observational study. Future Oncology, 2014, 10, 1611-1617.	1.1	8
46	The underestimated role of somatostatin analogs in the NETTER-1 trial. Future Oncology, 2017, 13, 1287-1289.	1.1	8
47	Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. Endocrine, 2017, 57, 512-517.	1.1	8
48	Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors. Frontiers in Oncology, 2019, 9, 902.	1.3	8
49	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482092727.	1.4	8
50	Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Targeted Oncology, 2011, 6, 181-186.	1.7	7
51	Article Commentary: Everolimus in Advanced Solid Tumors: When to Start, Early or Late?. Tumori, 2014, 100, e2-e3.	0.6	7
52	Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum. Cancers, 2012, 4, 808-820.	1.7	6
53	Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.. Journal of Clinical Oncology, 2013, 31, 4136-4136.	0.8	6
54	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. Future Oncology, 2017, 13, 1677-1683.	1.1	5

#	Article	IF	Citations
55	Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2021, 10, 1741.	1.0	5
56	Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes. Tumori, 2009, 95, 501-507.	0.6	4
57	Sunitinib and Everolimus in Pancreatic Neuroendocrine Tumors. Tumori, 2012, 98, 394-394.	0.6	4
58	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities A Case Report with a 6-Year Follow-Up. Case Reports in Oncology, 2016, 9, 432-439.	0.3	4
59	Update on medical treatment of small intestinal neuroendocrine tumors. Expert Review of Anticancer Therapy, 2016, 16, 969-976.	1.1	4
60	Compassionate Use of Everolimus in a Patient With a Neuroendocrine Tumor: A Case Report and Discussion of the Literature. Oncology Research, 2011, 19, 403-406.	0.6	4
61	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective. Frontiers in Oncology, 2022, 12, 780716.	1.3	4
62	Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. Tumori, 2013, 99, e148-51.	0.6	4
63	From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncology Reviews, 2009, 3, 79-87.	0.8	3
64	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. Future Oncology, 2019, 15, 3015-3024.	1.1	3
65	Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?. Oncologist, 2020, 25, e1257-e1258.	1.9	3
66	Everolimus in advanced solid tumors: when to start, early or late?. Tumori, 2014, 100, e2-3.	0.6	3
67	Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?. Annals of Oncology, 2013, 24, 1415-1416.	0.6	2
68	Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma. Frontiers in Oncology, 2021, 11, 628324.	1.3	2
69	Sunitinib and everolimus in pancreatic neuroendocrine tumors. Tumori, 2012, 98, 394.	0.6	2
70	Everolimus treatment in advanced solid tumors: a personal view. Future Science OA, 2015, 1, FSO3.	0.9	1
71	Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. International Journal of Colorectal Disease, 2015, 30, 429-430.	1.0	1
72	Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm. Scandinavian Journal of Gastroenterology, 2019, 54, 1111-1117.	0.6	1

#	Article	IF	Citations
73	NETs of the Lung. , 2021, , 163-178.		1
74	Update on Therapeutic Strategy in Lung Carcinoids. Journal of Cancer Therapy, 2013, 04, 1466-1471.	0.1	1